Shire received EU marketing authorization for its hemophilia drug

| By | Clinical Trials, Drug Development, Shire

Shire plc, the global biotechnology leader in rare diseases, announced today that the European Commission (EC) has granted Marketing Authorization for ADYNOVI [Antihemophilic Factor (Recombinant), PEGylated], an extended half-life recombinant factor VIII (rFVIII) treatment, for on-demand and prophylactic use in patients 12 years and older living with hemophilia A.

ADYNOVI is modified to last longer in the blood and potentially require less frequent injections than unmodified Antihemophilic Factor when used to reduce the frequency of bleeding. It is built on ADVATE® [Antihemophilic Factor (Recombinant)], a treatment used by hemophilia A patients worldwide for almost 15 years. ADYNOVI’s proprietary PEGylation technology, exclusively licensed from Nektar Therapeutics, extends the time between treatments and offers a twice-weekly dosing schedule.

“The European approval of ADYNOVI is an important milestone in our continued commitment to provide new treatment options for patients living with hemophilia A,” said Dr. Peter Foertig, MD, Global Head Hematology Medical Affairs, Shire. “We believe that the twice-weekly prophylactic dosing, as well as the on-demand control of bleeding, offered by ADYNOVI will bring us closer to our goal of improving and personalizing disease management for hemophilia A patients in Europe.”

The Marketing Authorization is based on outcomes from three Phase 3 clinical trials of patients with hemophilia A. Hemophilia A, designated an orphan disease by the EC, is a rare bleeding disorder that causes longer-than-normal bleeding due to lack of proper clotting factor VIII (FVIII) in the blood. 

With this approval, Shire is now authorized to market ADYNOVI in the 28 Member States of the European Union (EU), as well as in Iceland, Liechtenstein and Norway.

SOURCE: shire
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.